Trial Profile
An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 23 Jan 2019
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 15 Jan 2019 Status changed to discontinue.
- 29 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
- 29 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.